Press Room
7 October 2008
Human growth hormone (hGH): biosimilar pricing is not enough, convenience will mandate
After approval of three biosimilar hGH products, the pipeline is full of next generation hGH products with less frequent injection or non-injectable delivery
Read more10 September 2008
Takeda reigns supreme among Japanese pharma companies
Modest growth rates of 2007 sales by on average 3.2 % YoY reflects challenges imposed by the health care system and an aging product portfolio
Read more28 August 2008
Emerging diabetes drugs consider beta cell mass and function as an important target
The next generation of diabetes drugs still is focused on metabolic approaches, but activities to preserve or even regenerate pancreatic islet cell mass and function are gaining momentum
Read more12 August 2008
The third generation of TPO mimetics are again biologics
After failure of 1st generation thrombopoietic growth factors due to immunogencity, the 2nd generation is focused on oral TPO mimetics, now followed by a 3rd generation of engineered biologics with potential for higher potency and efficacy
Read more7 August 2008
The changing marketplace of antithrombotics: better than cheaper?
Next generation anticoagulant and antiplatelet agents have shown superiority over the current market leaders in clinical studies and are to challenge them before generics
Read more23 July 2008
Erythropoietins: the shift from biosimilars to “more for less” ESAs
Despite stagnant erythropoietin (EPO) sales, four new EPO products were introduced in Europe during the last year, but the pipeline shifts from biosimilar based approaches to next generation erythropoiesis stimulating agents (ESA)
Read more28 March 2008
Cancer and TNF antibodies boost Biologics Sales in 2007
Major cancer antibodies and anti-TNF antibodies superseded the erythropoietins from the top position of the best selling classes of Biologics in 2007 facilitated by the US$ currency exchange situation. Sales of major recombinant biologics were US$ 78 bln
Read more11 February 2008
2008 is a decisive year for the validation of the asthma target interleukin-13
Results of two major phase II studies in asthma expected during 2008 will be a GO/NO GO milestone for the field of interleukin-13 (IL-13) antagonists
Read more23 July 2007
114 Blockbuster Drugs Accounted for 2006 Sales of US$ 233.7 bln
The best selling blockbuster drug in 2006 was atorvastatin from Pfizer and Astellas Pharma with ww sales of US$ 13.6 bln. Biologics made 23.1 % of the total blockbuster drug sales of US$ 233.7 bln generated by 114 blockbuster drugs…
Read more30 May 2007
The imminent change of the antithrombotics market
The antithrombotics market with the two blockbusters enoxaparin and prasugrel is challenged by generic products as well as by next generation anticoagulants with oral administration and antithrombotics with an improved risk-benefit ratio
Read more2 May 2007
Up and down with cholesterol management
Sales of statins have reached a plateau, the imminent decline may be slowed by combination with cholesterol absorption inhibitors; future direction of R&D is focused on increasing HDL cholesterol. Related Competitor Analysis: Cholesterol Management
Read more25 April 2007
Beyond biogenerics: the real threats for therapeutic proteins
The biogenerics industry consolidates with Indian players emerging in Western countries; pegylation, protein engineering, drug delivery and oral small molecules feed the pipeline of next generation competitors of therapeutic proteins
Read moreFeatured Reports
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
RElated News